Blog
RSS FeedPosted by Michael Wonder on 27 Mar 2024
PHARMAC funds new treatments for breast and blood cancer
27 March 2024 - PHARMAC is funding two new cancer treatments, one for advanced breast cancer (ribociclib succinate) and one ...
Posted by Michael Wonder on 26 Mar 2024
Cost and value of cancer medicines in a single payer public health system in Ontario, Canada: a cross-sectional study
26 March 2024 - We describe temporal trends in expenditure on cancer medicines within the single-payer health system of Ontario, Canada, ...
Posted by Michael Wonder on 07 Mar 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
28 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Mar 2024
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments
6 March 2024 - NICE has published final evidence-based recommendations on the use of epcoritamab (Tepkinly) for the treatment of ...
Posted by Michael Wonder on 06 Mar 2024
NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources
6 March 2024 - NICE has published final draft guidance that does not recommend Enhertu (trastuzumab deruxtecan; Daiichi Sankyo) for treating ...
Posted by Michael Wonder on 05 Mar 2024
New treatment option available today for womb cancer
5 March 2024 - A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent ...
Posted by Michael Wonder on 04 Mar 2024
Tebentafusp in uveal melanoma: indication of a considerable additional benefit
1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...
Posted by Michael Wonder on 22 Feb 2024
Busy dad with leukaemia getting 'outdated treatment'
23 February 2024 - A West Coast dad is receiving “outdated treatment” for his leukaemia because PHARMAC’s policies are blocking ...
Posted by Michael Wonder on 22 Feb 2024
A cancer doctor’s view of why reform of PHARMAC is vital
23 February 2024 - Late last year, many of my colleagues returned from the largest international gathering of doctors who ...
Posted by Michael Wonder on 21 Feb 2024
Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...
Posted by Michael Wonder on 13 Feb 2024
PHARMAC to fund new treatments for breast and blood cancer
14 February 2024 - PHARMAC is funding two new cancer treatments, for advanced breast cancer, and for blood cancer, which will ...
Posted by Michael Wonder on 11 Feb 2024
Desperate PHARMAC plea from family selling cans for unfunded myeloma cancer drugs
11 February 2024 - Multiple myeloma, a common blood cancer, is incurable, but can be survived for years with the right ...
Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...
Posted by Michael Wonder on 07 Feb 2024
Nivolumab with relatlimab for the treatment of patients with unresectable or metastatic melanoma
7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the ...
Posted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...